Charcot-Marie-Tooth disease

dart board miss failure
Biotech

Applied's rare disease drug suffers another phase 3 failure

Applied’s rare disease drug has failed another late-stage clinical trial, adding to the woes of a candidate rejected by the FDA five months ago.
James Waldron May 19, 2025 7:20am
Missed target failed trial trial failure

Pharnext blames ‘unexpected’ placebo results for phase 3 failure

Dec 11, 2023 9:18am
Fail sign

Acceleron ditches midstage drug after flop

Mar 10, 2020 7:20am
skyscrapers

Neurogene nets $68.5M to advance therapies for neuro diseases

Feb 12, 2019 7:47am